Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.58 |
| ▸ | FLT4 | P35916 | 2/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001189 | 1.00 | MAPT (0.64) | MAPTKMT2ANPC1TDP1GAA | |
| SCHEMBL14375845 | 0.82 | RET (0.62) | RETPDGFRBRPS6KA3 | |
| SCHEMBL14376387 | 0.82 | MEN1 (0.57) | KMT2ATLK2KDRALKMEN1 | |
| SCHEMBL14376567 | 0.80 | TLK2 (0.66) | MAPTNPC1TLK2GSK3BKDR | |
| SCHEMBL15896534 | 0.79 | SRC (0.46) | TLK2KDRALKRETFGFR1 | |
| SCHEMBL14375844 | 0.78 | TLK2 (0.52) | MAPTNPC1TLK2GSK3BKDR | |
| SCHEMBL15896535 | 0.77 | LRRK2 (0.70) | MAPTNPC1TLK2GSK3BKDR | |
| SCHEMBL14375862 | 0.76 | RET (0.67) | MAPTNPC1TLK2GSK3BKDR | |
| SCHEMBL5728045 | 0.74 | TLK2 (1.00) | MAPTTLK2GSK3BKDRMAPK1 | |
| SCHEMBL5728041 | 0.74 | TLK2 (1.00) | MAPTTLK2GSK3BKDRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| EP-0769947-B1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 2001-05-02 | — | — | EP | claimed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | claimed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6846839-B1 | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis | SUGEN, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | MAPT 4430/4885KMT2A 1672/4885NPC1 2762/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | MAPT 4608/4885KMT2A 1485/4885NPC1 2433/4885 |
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | MAPT 67/4885KMT2A 1348/4885NPC1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.